NEU 3.50% $14.05 neuren pharmaceuticals limited

Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial, page-27

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,168 Posts.
    lightbulb Created with Sketch. 572
    Interesting to see what market thinks of this Ann today.

    Momentum building in share price leading up to this Ann and no increase yesterday.

    Clearly not marked as price sensitive but the wording suggesting confidence, can't see them "looking forward" or it being "ground breaking" if unsuccessful results being announced in Dec.

    This Ann yesterday should bolster confidence in Neu's position and increase buying Neu currently undervalued on Daybue alone, leading into what seems inevitable positive results in PMS in Dec.

    We should be humming to $20 now and on Ann day of success $25 -$30 absolute base case, I think we 100% agree on this type of valuation now.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.